(Q34013578)

30 July 2017

1 reference

title

The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery (English)

1 reference

30 July 2017

0 references

1 reference

Bardelmeijer HA

1

1 reference

30 July 2017

van Tellingen O

series ordinal

2

1 reference

30 July 2017

Schellens JH

series ordinal

3

1 reference

30 July 2017

Beijnen JH

series ordinal

4

1 reference

30 July 2017

publication date

1 August 2000

1 reference

Investigational New Drugs

30 July 2017

published in

1 reference

30 July 2017

volume

18

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

231-241

1 reference

Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test

30 July 2017

cites work

1 reference

12 December 2020

Effect of caffeine on the oral absorption and disposition of quinidine.

1 reference

12 December 2020

Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine

1 reference

12 December 2020

[SDZ PSC 833: a novel modulator of MDR].

1 reference

12 December 2020

5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil

1 reference

12 December 2020

CYP3A gene expression in human gut epithelium

1 reference

12 December 2020

Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration

1 reference

12 December 2020

Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.

1 reference

12 December 2020

Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers

1 reference

12 December 2020

Clinical trials of P-glycoprotein reversal in solid tumours

1 reference

12 December 2020

Compliance with oral chemotherapy in childhood lymphoblastic leukaemia

1 reference

12 December 2020

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

1 reference

12 December 2020

Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors

1 reference

12 December 2020

Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes

1 reference

12 December 2020

Variable bioavailability following repeated oral doses of etoposide

1 reference

12 December 2020

The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation

1 reference

12 December 2020

In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.

1 reference

12 December 2020

Clinical pharmacology of 5-fluorouracil

1 reference

12 December 2020

Bioavailability and pharmacokinetics of etoposide (VP-16)

1 reference

12 December 2020

Pharmacokinetics of navelbine after oral administration in cancer patients

1 reference

12 December 2020

Cyclosporin metabolism by human gastrointestinal mucosal microsomes

1 reference

12 December 2020

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

12 December 2020

Treatment of non-small-cell lung cancer with prolonged oral etoposide

1 reference

12 December 2020

Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer

1 reference

12 December 2020

Relative bioavailability of two oral formulations of navelbine in cancer patients

1 reference

12 December 2020

Oral chemotherapy: rationale and future directions

1 reference

12 December 2020

Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications.

1 reference

12 December 2020

Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies

1 reference

12 December 2020

Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity

1 reference

12 December 2020

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance

1 reference

12 December 2020

Biochemistry of multidrug resistance mediated by the multidrug transporter

1 reference

12 December 2020

The influence of food on the absorption and metabolism of drugs: an update

1 reference

12 December 2020

Navelbine: a new step in cancer therapy?

1 reference

12 December 2020

Human P-glycoprotein transports cyclosporin A and FK506.

1 reference

12 December 2020

Inhibition of intestinal P-glycoprotein and effects on etoposide absorption.

1 reference

12 December 2020

Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein

1 reference

12 December 2020

Review: first-pass metabolism by the gastrointestinal mucosa.

1 reference

12 December 2020

Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells

1 reference

12 December 2020

Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir

1 reference

12 December 2020

Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells

1 reference

12 December 2020

Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A

1 reference

12 December 2020

Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein.

1 reference

12 December 2020

Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A

1 reference

12 December 2020

The oral fluorouracil prodrugs

1 reference

12 December 2020

Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.

1 reference

12 December 2020

Extrahepatic metabolism of drugs in humans

1 reference

12 December 2020

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

1 reference

12 December 2020

Co-administration of cyclosporin enables oral therapy with paclitaxel

1 reference

12 December 2020

The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine*

1 reference

12 December 2020

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

1 reference

12 December 2020

1 reference

12 December 2020

Patient compliance with crucial drug regimens: implications for prostate cancer.

1 reference

12 December 2020

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

1 reference

12 December 2020

Bioavailability and pharmacology of oral idarubicin

1 reference

12 December 2020

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor

1 reference

12 December 2020

Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein

1 reference

12 December 2020

CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein

1 reference

12 December 2020

Characterization of human cytochrome P450 enzymes

1 reference

12 December 2020

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

1 reference

12 December 2020

Chronic etoposide administration: overview of clinical experience

1 reference

12 December 2020

Relative effects of different surfactants on intestinal absorption and the release of proteins and phospholipids from the tissue

1 reference

12 December 2020

Drug binding to P-glycoprotein is inhibited in normal tissues following SDZ-PSC 833 treatment

1 reference

12 December 2020

Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum

1 reference

12 December 2020

Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893).

1 reference

12 December 2020

Reduced Oral Etoposide Bioavailability in Patients With Advanced Cancer of the Head and Neck

1 reference

12 December 2020

Enhancement effect of methylxanthines on the intestinal absorption of poorly absorbable dyes from the rat small intestine

1 reference

12 December 2020

A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration

1 reference

12 December 2020

Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients

1 reference

12 December 2020

Population pharmacokinetics of total and unbound etoposide.

1 reference

12 December 2020

P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity

1 reference

12 December 2020

Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines

1 reference

12 December 2020

The effect of dose on the bioavailability of oral etoposide.

1 reference

12 December 2020

An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients

1 reference

12 December 2020

Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infus

1 reference

12 December 2020

Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.

1 reference

12 December 2020

P-glycoprotein content and mediation of vincristine efflux: correlation with the level of differentiation in luminal epithelium of mouse small intestine.

1 reference

12 December 2020

Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver

1 reference

12 December 2020

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase

1 reference

12 December 2020

Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve

1 reference

12 December 2020

First-pass metabolism of cyclosporin by the gut

1 reference

12 December 2020

Gastrointestinal absorption of drugs

1 reference

12 December 2020

Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil

1 reference

12 December 2020

In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833

1 reference

12 December 2020

Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.

1 reference

12 December 2020

Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice

1 reference

12 December 2020

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

1 reference

12 December 2020

The biochemistry of P-glycoprotein-mediated multidrug resistance

1 reference

12 December 2020

Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial

1 reference

12 December 2020

Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine

1 reference

12 December 2020

Pharmacology, bio-analysis and pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives (review).

1 reference

12 December 2020

Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme

1 reference

12 December 2020

Pharmacokinetics of ftorafur after intravenous and oral administration

1 reference

12 December 2020

Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells

1 reference

12 December 2020

In vitro and in vivo modulation of multi-drug resistance with amiodarone

1 reference

12 December 2020

UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer

1 reference

12 December 2020

Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide.

1 reference

12 December 2020

Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins

1 reference

12 December 2020

MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype

1 reference

12 December 2020

Enzymes of uracil catabolism in normal and neoplastic human tissues

1 reference

12 December 2020

Pharmacokinetics of VP16-213 given by different administration methods

1 reference

12 December 2020

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

1 reference

12 December 2020

Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A phase II study

1 reference

12 December 2020

The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate

1 reference

12 December 2020

Bioavailability of low-dose oral etoposide

1 reference

12 December 2020

Carrier-mediated intestinal transport of drugs

1 reference

12 December 2020

5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1006469621561

1 reference

Dimensions Publication ID

30 July 2017

1047507061

0 references

1 reference